Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications - Scorecard - MDSpire
Advertisement
Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications
Clinical Scorecard: Case Study: Suspected Immune-Related Myocarditis Associated with Adebrelimab and Overlapping Myositis/Myasthenia Gravis Syndrome (IM3OS): A Rapidly Progressing Fatal Outcome and Its Clinical Significance
At a Glance
Category
Detail
Condition
Immune-related myocarditis with myositis/myasthenia gravis overlap syndrome (IM3OS)
Key Mechanisms
Excessive activation of T cells induced by immune checkpoint inhibitors leading to concurrent infiltration of the heart, skeletal muscle, and neuromuscular junction.
Target Population
Elderly patients, median age 70 years, with a male predominance.
Care Setting
Oncology and cardiology units managing immune-related adverse events.
Key Highlights
Acute symptoms developed 3 days after the second cycle of adebrelimab.
Significant elevation of myocardial injury markers observed.
High in-hospital mortality rate (38% to 60%) associated with IM3OS.
Rapid disease progression with cardiac arrest occurring on day 9.
Need for early recognition and aggressive immunosuppressive therapy.
Guideline-Based Recommendations
Diagnosis
Monitor for symptoms of myocarditis and myositis in patients receiving immune checkpoint inhibitors.
Management
Immediate drug discontinuation and initiation of corticosteroids and intravenous immune globulin.
Monitoring & Follow-up
Regular assessment of cardiac biomarkers and electrocardiogram changes.
Risks
Potential for rapid onset of severe symptoms and high mortality.
Patient & Prescribing Data
Elderly patients with advanced malignancies receiving immune checkpoint inhibitors.
Combination therapy with immune checkpoint inhibitors may lead to severe immune-related adverse events.
Clinical Best Practices
Conduct rigorous baseline assessments before initiating treatment.
Implement coordinated multidisciplinary management for suspected IM3OS.
Educate patients on the signs and symptoms of immune-related adverse events.
